Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of Anti-PD-1
antibody SHR-1210 plus apatinib as second-line treatment of advanced esophageal squamous
cell.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University